Abstract:The liver is a critical system for metabolism in human beings, which plays an essential role in an abundance of physiological processes and is vulnerable to endogenous or exogenous injuries. After the damage to the liver, a type of aberrant wound healing response known as liver fibrosis may happen, which can result in an excessive accumulation of extracellular matrix (ECM) and then cause cirrhosis or hepatocellular carcinoma (HCC), seriously endangering human health and causing a great economic burden. However, few effective anti-fibrotic medications are clinically available to treat liver fibrosis. The most efficient approach to liver fibrosis prevention and treatment currently is to eliminate its causes, but this approach’s efficiency is too slow, or some causes cannot be fully eliminated, which causes liver fibrosis to worsen. In cases of advanced fibrosis, the only available treatment is liver transplantation. Therefore, new treatments or therapeutic agents need to be explored to stop the further development of early liver fibrosis or to reverse the fibrosis process to achieve liver fibrosis resolution. Understanding the mechanisms that lead to the development of liver fibrosis is necessary to find new therapeutic targets and drugs. The complex process of liver fibrosis is regulated by a variety of cells and cytokines, among which hepatic stellate cells (HSCs) are the essential cells, and their continued activation will lead to further progression of liver fibrosis. It has been found that inhibiting HSC activation, or inducing apoptosis, and inactivating activated hepatic stellate cells (aHSCs) can reverse fibrosis and thus achieve liver fibrosis regression. Hence, this review will concentrate on how HSCs become activated during liver fibrosis, including intercellular interactions and related signaling pathways, as well as targeting HSCs or liver fibrosis signaling pathways to achieve the resolution of liver fibrosis. Finally, new therapeutic compounds targeting liver fibrosis are summarized to provide more options for the therapy of liver fibrosis.

Molecular mechanism of hepatic stellate cell activation and antifibrotic therapeutic strategies

Regulatory Long Non-Coding RNAs of Hepatic Stellate Cells in Liver Fibrosis (Review)

Activation and Inhibition of Human HSCs and the Related Molecular Mechanisms

Modulation of hepatic stellate cells and reversibility of hepatic fibrosis.

Intercellular crosstalk of hepatic stellate cells in liver fibrosis: New insights into therapy

Mechanisms of hepatic stellate cell activation

Liver fibrosis and hepatic stellate cells: Etiology, pathological hallmarks and therapeutic targets

Therapeutic potential of targeting regulatory mechanisms of hepatic stellate cell activation in liver fibrosis

The Progression for the Therapy of Liver Fibrosis Targeting to Hepatic Stellate Cells

Clearance of Activated Stellate Cells for Hepatic Fibrosis Regression: Molecular Basis and Translational Potential

Hepatic stellate cells: a target for the treatment of liver fibrosis

[Mechanism of Hepatic Stellate Cell Migration During Liver Fibrosis].

Liver Fibrosis Resolution: from Molecular Mechanisms to Therapeutic Opportunities

Epigenetic Mechanisms in Hepatic Stellate Cell Activation During Liver Fibrosis and Carcinogenesis

Pathophysiological mechanisms of hepatic stellate cells activation in liver fibrosis

Targeted Drug Delivery to Hepatic Stellate Cells for the Treatment of Liver Fibrosis

Hepatic Stellate Cells as a Target for the Treatment of Liver Fibrosis

Hepatic stellate cells as key target in liver fibrosis

Mechanical homeostasis imbalance in hepatic stellate cells activation and hepatic fibrosis

Expression of hepatic stellate cell activation-related genes in HBV-, HCV-, and nonalcoholic fatty liver disease-associated fibrosis